A Phase 3 interventional study of pitavastatin and simvastatin in Hypercholesterolemia and Dyslipidemia, sponsored by Kowa Research Europe. Completed at 35 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-03-16.
Sponsored by Kowa Research Europe (part of Kowa Company, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing pitavastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. pitavastatin · Hypercholesterolemia.
Among the 19 studies testing pitavastatin in Hypercholesterolemia, this one is the 6th largest by enrollment, is one of 5 that started in 2005, is one of 9 in phase 3, and was the 5th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →None of the 19 studies testing pitavastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2005.
This study's enrollment of 355 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 200 across the 19 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kowa Research Europe, one of the names counted as Kowa Company, Ltd.. Under that name alone:
Kowa Research Europe is the lead sponsor of 10 studies on the registry; none are open to participants now.
11 studies in Hypercholesterolemia by Kowa Company, Ltd.: 1 open now, 1 under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Hypercholesterolemia by Kowa Company, Ltd., this one is the 6th largest by enrollment, is one of 4 that started in 2005, is one of 10 in phase 3, and was the 4th registered.
Kowa Company, Ltd.’s Hypercholesterolemia studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing pitavastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Kowa Company, Ltd.’s 11 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of pitavastatin with that of simvastatin in patients with risk factors for heart disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pitavastatin 4 mg once daily
Drug: pitavastatin
Simvastatin 40 mg once daily
Drug: simvastatin
Percent Change From Baseline in LDL-C
Percent change from baseline in low density lipoprotein-cholesterol (LDL-C)
Time frame: 12 weeks
Number of Patients Attaining NCEP LDL-C Target (< 160 mg/dL)
Number of patients attaining LDL-C target according to National Cholesterol Education Program (NCEP) criteria (\< 160 mg/dL)
Time frame: 12 weeks
Subjects were enrolled from September 2005 to October 2006 at 43 investigator sites.
| Milestone | Pitavastatin 4 mg QD | Simvastatin 40 mg QD |
|---|---|---|
| Started | 236 | 119 |
| Safety population | 233 | 119 |
| Completed | 223 | 107 |
| Not completed | 13 | 12 |
Percent change from baseline in low density lipoprotein-cholesterol (LDL-C)
| mg/dL | Pitavastatin 4 mg QD | Simvastatin 40 mg QD |
|---|---|---|
| Percent Change From Baseline in LDL-C | -43.96 ± 12.770 | -43.77 ± 14.416 |
Number of patients attaining LDL-C target according to National Cholesterol Education Program (NCEP) criteria (\< 160 mg/dL)
| participants | Pitavastatin 4 mg QD | Simvastatin 40 mg QD |
|---|---|---|
| Number of Patients Attaining NCEP LDL-C Target (< 160 mg/dL) | 203 | 101 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pitavastatin 4 mg QD | — | — | — |
| Simvastatin 40 mg QD | — | — | — |
| Event | Pitavastatin 4 mg QD | Simvastatin 40 mg QD |
|---|---|---|
| LymphadenopathyBlood and lymphatic system disorders | 0/233 | 1/119 |
| cholelithiasisHepatobiliary disorders | 0/233 | 1/119 |
| CystitisInfections and infestations | 0/233 | 1/119 |
| SyncopeNervous system disorders | 0/233 | 1/119 |
| Aortic aneurysmVascular disorders | 0/233 | 1/119 |
| Acute coronary syndromeCardiac disorders | 1/233 | 0/119 |
| Myocardial infarctionCardiac disorders | 1/233 | 0/119 |
| GastritisGastrointestinal disorders | 1/233 | 0/119 |
| peritonsilar abscessInfections and infestations | 1/233 | 0/119 |
| Event | Pitavastatin 4 mg QD | Simvastatin 40 mg QD |
|---|---|---|
| HeadacheNervous system disorders | 13/233 | 3/119 |
| NasopharyngitisInfections and infestations | 11/233 | 3/119 |
| ConsitpationGastrointestinal disorders | 10/233 | 2/119 |
| HypertensionVascular disorders | 10/233 | 0/119 |
| MyalgiaMusculoskeletal and connective tissue disorders | 7/233 | 5/119 |
| Age, Categorical(Participants) | Pitavastatin 4 mg QD | Simvastatin 40 mg QD | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 184 | 88 | 272 |
| >=65 years | 49 | 31 | 80 |
| Age Continuous(years) | Pitavastatin 4 mg QD | Simvastatin 40 mg QD | Total |
|---|---|---|---|
| Mean | 60.1 ± 6.82 | 60.9 ± 6.78 | 60.3 ± 6.81 |
| Sex: Female, Male(Participants) | Pitavastatin 4 mg QD | Simvastatin 40 mg QD | Total |
|---|---|---|---|
| Female | 75 | 37 | 112 |
| Male | 158 | 82 | 240 |
The record gives a start of Sep 2005, a primary completion of Oct 2006 and a completion of Oct 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitavastatin